Internis

Internis Pharmaceuticals Limited is a UK-based pharmaceutical company specializing in the development and commercialization of medicines. Founded in 2010 and headquartered in Huddersfield, West Yorkshire, the firm focuses on treatments for bone disorders like osteoporosis and vitamin D3 deficiency.

The company's product portfolio includes a range of prescription and over-the-counter (OTC) offerings, vitamins, and supplements. Notable products are Accrete D3, Binosto, and the Fultium-D3 range, which comes in various formulations including capsules and drops. The Fultium-D3 drops were the first commercially available prescription treatment for vitamin D deficiency in children under five, pregnant women, and breastfeeding mothers in the UK. The active ingredient in many of its key products is colecalciferol (vitamin D3), which is used to regulate calcium metabolism and its incorporation into bone tissue.

Internis operates as part of the Thornton and Ross group, which was subsequently acquired by STADA. The company's business model involves in-house research and development, manufacturing, and marketing. Its stated mission is to address unmet medical needs through both internal innovation and strategic licensing. Internis products are distributed to thousands of retail pharmacies and hospitals.

Keywords: colecalciferol, vitamin D3 deficiency, osteoporosis, bone disorders, pharmaceutical manufacturing, prescription medicines, OTC products, Fultium-D3, Accrete D3, Binosto, calcium metabolism, UK pharmaceuticals, Huddersfield, vitamin supplements